Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Canakinumab Treatment Effective for Familial Mediterranean Fever

Lara C. Pullen, PhD  |  April 23, 2018

The case series suggests the effect of a single dose of canakinumab appears quite quickly. The authors note that although the additive immunosuppressive effect of canakinumab may be a concern in this patient population, they did not observe infections in Cases 1 and 3. The second patient had recurrent urinary tract infections before and after the start of canakinumab treatment.


Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Laskari K, Boura P, Dalekos GN, et al. Long-term beneficial effect of canakinumab in colchicine-resistant familial mediterranean fever. J Rheumatol. 2017 Jan;44(1):102–109. doi: 10.3899/jrheum.160518. Epub 2016 Nov 15.
  2. van der Hilst JCh, Moutschen M, Messiaen PE, et al. Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature. Biologics. 2016 Apr 4;10:75–80. doi: 10.2147/BTT.S102954. eCollection 2016.
  3. Yildirim T, Yilmaz R, Uzerk Kibar M, et al. Canakinumab treatment in renal transplant recipients with familial Mediterranean fever. J Nephrol. 2018 Feb 14. doi: 10.1007/s40620-018-0475-5. [Epub ahead of print]

Page: 1 2 | Single Page
Share: 

Filed under:Conditions Tagged with:canakinumabFamilial Mediterranean feverkidney transplantRenaltransplantation

Related Articles

    Nature’s Inflammation Experiment

    August 1, 2008

    Familial Mediterranean fever a frequently misdiagnosed autoinflammatory disease

    S K Chavan / shutterstock.com

    Case Report: A Patient Helps Diagnose Familial Mediterranean Fever

    August 16, 2019

    Autoinflammatory diseases are genetically diverse, but clinically similar, conditions distinct from autoimmune illnesses, such as systemic lupus erythematosus or rheumatoid arthritis. Clinically, they are defined by recurrent episodes of inflammation that follow a characteristic pattern each time they occur. Some have a set length of time during which fever, peritonitis or arthritis manifest. Others are…

    Colchicine: An Ancient Drug with Modern Uses

    August 11, 2021

    Discovered more than 3,000 years ago, colchicine is one of the oldest drugs still in use today. Like most old remedies, colchicine is a chemical substance found in many plants, most notably in colchicum autumnale, known as wild saffron or autumn crocus. It was mentioned in the oldest Egyptian medical text, Ebers Papyrus (circa 1550…

    What Rheumatologists Need to Know about Identifying Amyloidosis

    June 1, 2013

    Although amyloidosis is not a rheumatic disease, rheumatologists may be the first to diagnose this life-threatening condition

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences